NewAmsterdam Pharma Company N.V. (NAMS)
| Market Cap | 4.14B +91.5% |
| Revenue (ttm) | 22.57M -52.1% |
| Net Income | -212.73M |
| EPS | -1.78 |
| Shares Out | 116.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 583,591 |
| Open | 35.86 |
| Previous Close | 35.74 |
| Day's Range | 35.01 - 36.73 |
| 52-Week Range | 16.79 - 42.21 |
| Beta | 0.03 |
| Analysts | Strong Buy |
| Price Target | 50.04 (+21.22%) |
| Earnings Date | May 7, 2026 |
About NAMS
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartere... [Read more]
Financial Performance
In 2025, NAMS's revenue was $22.50 million, a decrease of -50.61% compared to the previous year's $45.56 million. Losses were -$203.82 million, -15.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price target is $50.04, which is an increase of 21.22% from the latest price.
News
NewAmsterdam Pharma Company Transcript: RBC Capital Markets Global Healthcare Conference 2026
PREVAIL's design was updated to a modern 4-point MACE definition and increased event targets for robust efficacy, with interim analysis requiring significance in both 3- and 4-point MACE. Regulatory alignment and strong ancillary benefits position obicetrapib for broad adoption.
NewAmsterdam Pharma Company Transcript: Bank of America Global Healthcare Conference 2026
Phase III data show strong LDL and Lp(a) reductions, with additional benefits in diabetes and early Alzheimer's signals. Interim PREVAIL results are expected Q1 next year, with broad market potential driven by evolving guidelines and a large unmet need.
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compan...
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NewAmsterdam Pharma NASDAQ: NAMS said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what exe...
NewAmsterdam Pharma Company Transcript: Investor update
PREVAIL’s blinded data show lower than expected MACE rates and trends consistent with prior trials, prompting an interim analysis in Q4 2026. The trial is well powered, with robust design and encouraging signals across endpoints, and could enable earlier market entry if efficacy is demonstrated.
NewAmsterdam Pharma Company Slides: Investor update
NewAmsterdam Pharma Company has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches...
NewAmsterdam Pharma Company Quarterly report: Q1 2026
NewAmsterdam Pharma Company has published its Q1 2026 quarterly earnings report on May 7, 2026.
NewAmsterdam Pharma Company Earnings release: Q1 2026
NewAmsterdam Pharma Company released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
NewAmsterdam Pharma Company Proxy statement: Proxy filing
NewAmsterdam Pharma Company filed a proxy statement on May 6, 2026, providing details for shareholder voting and corporate governance matters.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compan...
NewAmsterdam Pharma Company Proxy statement: Proxy filing
NewAmsterdam Pharma Company filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
NewAmsterdam Pharma Company Transcript: 25th Annual Needham Virtual Healthcare Conference
Recent phase III data show strong LDL and MACE benefits, with additional advantages in diabetes and Alzheimer's biomarkers. U.S. and E.U. launches are on track, supported by robust financials and expanded leadership. Market opportunity is growing with new guidelines and broad clinical differentiation.
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...
NewAmsterdam Pharma initiated with a Buy at Truist
Truist initiated coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $57 price target The stock significantly outperformed in 2024 and 2025 as the company successfully de-risked its lead…
NewAmsterdam Pharma Company Transcript: Leerink Global Healthcare Conference 2026
Obicetrapib has shown strong LDL and Lp(a) lowering in phase III trials, with European approval and major outcome data expected this year. Commercial prospects are robust, with label expansion in diabetes and Alzheimer's prevention studies underway, and significant differentiation from competitors.
NewAmsterdam Pharma Company Transcript: TD Cowen 46th Annual Health Care Conference
Obicetrapib has shown robust LDL and Lp(a) lowering, strong tolerability, and a 21% MACE reduction in Phase III trials. Commercial launch in Europe is planned for late 2024, with PREVAIL outcomes data expected to drive U.S. uptake. Alzheimer's prevention and diabetes risk reduction are key differentiators.
NewAmsterdam Pharma Company Slides: Corporate presentation
NewAmsterdam Pharma Company has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
NAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim
Guggenheim raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $45 from $41 and keeps a Buy rating on the shares. In talks, management expressed confidence in the progress…
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking i...
NewAmsterdam Pharma Company Earnings release: Q4 2025
NewAmsterdam Pharma Company released its Q4 2025 earnings on February 18, 2026, summarizing the period's financial results.
NewAmsterdam Pharma Company Annual report: Q4 2025
NewAmsterdam Pharma Company has published its Q4 2025 annual report on February 18, 2026.
NewAmsterdam Pharma Company Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
PREVAIL and BROADWAY studies show aligned event rates, supporting confidence in outcomes. Obicetrapib stands out for its broad efficacy, safety, and convenience, with regulatory milestones expected in Europe and the U.S. this year. Commercial strategy targets a large, underserved population.